JP2017536401A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536401A5 JP2017536401A5 JP2017529637A JP2017529637A JP2017536401A5 JP 2017536401 A5 JP2017536401 A5 JP 2017536401A5 JP 2017529637 A JP2017529637 A JP 2017529637A JP 2017529637 A JP2017529637 A JP 2017529637A JP 2017536401 A5 JP2017536401 A5 JP 2017536401A5
- Authority
- JP
- Japan
- Prior art keywords
- solid dispersion
- arn
- formulation
- meth
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007962 solid dispersion Substances 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 17
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 claims description 16
- 229920000193 polymethacrylate Polymers 0.000 claims description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical group COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 238000001125 extrusion Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000006104 solid solution Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 11
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229960004103 abiraterone acetate Drugs 0.000 claims 1
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical group C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 238000010971 suitability test Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196591.3 | 2014-12-05 | ||
| EP14196591 | 2014-12-05 | ||
| PCT/US2015/063667 WO2016090101A1 (en) | 2014-12-05 | 2015-12-03 | Anticancer compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536401A JP2017536401A (ja) | 2017-12-07 |
| JP2017536401A5 true JP2017536401A5 (https=) | 2019-01-17 |
| JP6767368B2 JP6767368B2 (ja) | 2020-10-14 |
Family
ID=52006905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529637A Active JP6767368B2 (ja) | 2014-12-05 | 2015-12-03 | 抗癌性組成物 |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20170360707A1 (https=) |
| EP (2) | EP3842034B1 (https=) |
| JP (1) | JP6767368B2 (https=) |
| KR (1) | KR102348325B1 (https=) |
| CN (2) | CN106999430A (https=) |
| AR (1) | AR102924A1 (https=) |
| AU (1) | AU2015358493B2 (https=) |
| CA (1) | CA2969661C (https=) |
| CL (1) | CL2017001372A1 (https=) |
| CO (1) | CO2017005573A2 (https=) |
| CR (1) | CR20170217A (https=) |
| CY (1) | CY1123856T1 (https=) |
| DK (1) | DK3226842T3 (https=) |
| EA (1) | EA035988B1 (https=) |
| ES (2) | ES2839128T3 (https=) |
| HR (1) | HRP20201902T1 (https=) |
| HU (1) | HUE051888T2 (https=) |
| IL (1) | IL252324B (https=) |
| LT (1) | LT3226842T (https=) |
| MA (2) | MA41108B1 (https=) |
| MD (1) | MD3226842T2 (https=) |
| MX (1) | MX384382B (https=) |
| NI (1) | NI201700069A (https=) |
| PL (1) | PL3226842T3 (https=) |
| PT (1) | PT3226842T (https=) |
| RS (1) | RS61466B1 (https=) |
| SG (1) | SG11201704264UA (https=) |
| SI (1) | SI3226842T1 (https=) |
| TW (1) | TWI683662B (https=) |
| UA (1) | UA121123C2 (https=) |
| WO (1) | WO2016090101A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201501870RA (en) | 2012-09-26 | 2015-04-29 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| WO2016090098A1 (en) | 2014-12-05 | 2016-06-09 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
| ES3019912T3 (en) | 2014-12-05 | 2025-05-21 | Aragon Pharmaceuticals Inc | Anticancer compositions |
| AU2018351714A1 (en) | 2017-10-16 | 2020-04-30 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| JP7244536B2 (ja) * | 2018-04-06 | 2023-03-22 | キャプシュゲル・ベルジウム・エヌ・ヴィ | メタクリル酸メチル－メタクリル酸コポリマーからなる低アスペクト比の粒子のための噴霧乾燥方法 |
| WO2020144647A1 (en) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Pharmaceutical composition comprising apalutamide dispersed in apple sauce |
| AU2020215177A1 (en) | 2019-01-30 | 2021-08-12 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| TWI840496B (zh) | 2019-01-30 | 2024-05-01 | 美商艾瑞岡醫藥公司 | 用於治療轉移性去勢敏感性前列腺癌之抗雄性激素 |
| WO2020239478A1 (en) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectedin for treating sarcomas based on genomic markers |
| EP4054572A1 (en) | 2019-11-04 | 2022-09-14 | Aragon Pharmaceuticals, Inc. | Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment |
| WO2021245285A1 (en) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| TW202228794A (zh) | 2020-09-04 | 2022-08-01 | 美商艾瑞岡醫藥公司 | 用於治療前列腺癌之方法 |
| WO2022195407A1 (en) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| WO2023152611A1 (en) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
| KR20250157532A (ko) | 2023-03-16 | 2025-11-04 | 바이엘 컨수머 케어 악티엔게젤샤프트 | 호르몬 감수성 전립선암의 생화학적 재발이 있는 환자의 치료를 위한 안드로겐 수용체 길항제 |
| WO2026052846A1 (en) | 2024-09-09 | 2026-03-12 | Synthon B.V. | Pharmaceutical formulation comprising apalutamide |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1381358B1 (en) | 2001-04-02 | 2006-05-03 | Astrazeneca AB | Solid pharmaceutical composition comprising 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp |
| WO2003077827A1 (en) * | 2002-03-19 | 2003-09-25 | Nippon Shinyaku Co., Ltd. | Process for producing drug solid dispersion |
| CA2549572A1 (en) * | 2003-12-15 | 2005-06-23 | Council Of Scientific & Industrial Research | Taste masked pharmaceutical compositions comprising bitter drug and ph sensitive polymer |
| LT2656842T (lt) * | 2006-03-27 | 2016-09-26 | The Regents Of The University Of California | Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui |
| WO2011103202A2 (en) * | 2010-02-16 | 2011-08-25 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| EP2721003B1 (en) * | 2011-06-15 | 2018-01-03 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
| WO2013152342A1 (en) * | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| EA201992010A1 (ru) | 2012-06-07 | 2020-01-24 | Арагон Фармасьютикалз, Инк. | Кристаллическая форма а 4-[7-(6-циано-5-трифторметилпиридин-3-ил)-8-оксо-6-тиоксо-5,7-диазаспиро[3.4]окт-5-ил]-2-фтор-n-метилбензамида для лечения заболевания или состояния, связанного с активностью андрогенных рецепторов, включая рак простаты |
| US10668156B2 (en) | 2012-06-22 | 2020-06-02 | Basf Se | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers |
| WO2014043208A1 (en) * | 2012-09-11 | 2014-03-20 | Medivation Prostate Therapeutics, Inc. | Formulations of enzalutamide |
| SG11201501870RA (en) * | 2012-09-26 | 2015-04-29 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| SG10201907684PA (en) * | 2013-01-15 | 2019-10-30 | Aragon Pharmaceuticals Inc | Androgen receptor modulator and uses thereof |
| CN112353762A (zh) * | 2013-01-22 | 2021-02-12 | 霍夫曼-拉罗奇有限公司 | 具有改善的生物利用度的药物组合物 |
| WO2014167428A2 (en) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| CA2920317A1 (en) * | 2013-08-12 | 2015-02-19 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| CA2940984A1 (en) * | 2014-02-05 | 2015-08-13 | Lek Pharmaceuticals D.D. | Solid pharmaceutical compositions of androgen receptor antagonists |
-
2015
- 2015-12-03 ES ES15817642T patent/ES2839128T3/es active Active
- 2015-12-03 MA MA41108A patent/MA41108B1/fr unknown
- 2015-12-03 CN CN201580066192.9A patent/CN106999430A/zh active Pending
- 2015-12-03 EP EP20209559.2A patent/EP3842034B1/en active Active
- 2015-12-03 HR HRP20201902TT patent/HRP20201902T1/hr unknown
- 2015-12-03 AU AU2015358493A patent/AU2015358493B2/en active Active
- 2015-12-03 SG SG11201704264UA patent/SG11201704264UA/en unknown
- 2015-12-03 PL PL15817642T patent/PL3226842T3/pl unknown
- 2015-12-03 US US15/533,203 patent/US20170360707A1/en not_active Abandoned
- 2015-12-03 MA MA055404A patent/MA55404A/fr unknown
- 2015-12-03 CA CA2969661A patent/CA2969661C/en active Active
- 2015-12-03 UA UAA201707016A patent/UA121123C2/uk unknown
- 2015-12-03 LT LTEP15817642.0T patent/LT3226842T/lt unknown
- 2015-12-03 EA EA201791252A patent/EA035988B1/ru unknown
- 2015-12-03 JP JP2017529637A patent/JP6767368B2/ja active Active
- 2015-12-03 PT PT158176420T patent/PT3226842T/pt unknown
- 2015-12-03 HU HUE15817642A patent/HUE051888T2/hu unknown
- 2015-12-03 KR KR1020177018240A patent/KR102348325B1/ko active Active
- 2015-12-03 EP EP15817642.0A patent/EP3226842B1/en active Active
- 2015-12-03 SI SI201531519T patent/SI3226842T1/sl unknown
- 2015-12-03 CR CR20170217A patent/CR20170217A/es unknown
- 2015-12-03 ES ES20209559T patent/ES3021508T3/es active Active
- 2015-12-03 RS RS20210184A patent/RS61466B1/sr unknown
- 2015-12-03 CN CN202211487545.0A patent/CN115837010B/zh active Active
- 2015-12-03 MD MDE20170153T patent/MD3226842T2/ro not_active IP Right Cessation
- 2015-12-03 WO PCT/US2015/063667 patent/WO2016090101A1/en not_active Ceased
- 2015-12-03 TW TW104140458A patent/TWI683662B/zh not_active IP Right Cessation
- 2015-12-03 MX MX2017007201A patent/MX384382B/es unknown
- 2015-12-03 DK DK15817642.0T patent/DK3226842T3/da active
- 2015-12-04 AR ARP150103980A patent/AR102924A1/es unknown
-
2017
- 2017-05-16 IL IL252324A patent/IL252324B/en unknown
- 2017-05-29 CL CL2017001372A patent/CL2017001372A1/es unknown
- 2017-06-02 NI NI201700069A patent/NI201700069A/es unknown
- 2017-06-05 CO CONC2017/0005573A patent/CO2017005573A2/es unknown
-
2021
- 2021-01-27 CY CY20211100068T patent/CY1123856T1/el unknown
- 2021-12-13 US US17/549,495 patent/US20220151931A1/en not_active Abandoned
-
2024
- 2024-05-10 US US18/661,226 patent/US20240293321A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536401A5 (https=) | ||
| JP2017536398A5 (https=) | ||
| JP2017536407A5 (https=) | ||
| JP2019517497A5 (https=) | ||
| HRP20211140T1 (hr) | Pripravci protiv raka | |
| HRP20201902T1 (hr) | Pripravci protiv raka | |
| HRP20241719T1 (hr) | Antitumorske smjese | |
| CN103550165B (zh) | 一种含有利伐沙班的药物组合物及其制备方法 | |
| JP2014516080A5 (https=) | ||
| JP2012236837A5 (https=) | ||
| JP2013199488A5 (https=) | ||
| JP6470257B2 (ja) | 分散安定化剤としてポリエチレングリコール系高分子及び／またはビニルピロリドン系高分子を含むタダラフィル遊離塩基含有フィルム剤形 | |
| JP2009502487A5 (https=) | ||
| JP2012153724A5 (https=) | ||
| JP2009502969A5 (https=) | ||
| JP2011225600A5 (https=) | ||
| JP2014528431A5 (https=) | ||
| CN101808622A (zh) | 含有埃索美拉唑的药物组合物 | |
| BR112013028453B1 (pt) | Uso de uma composição de revestimento, formas de dosagem farmacêuticas ou nutracêuticas gastrorresistentes, e composição do polímero do núcleo/invólucro | |
| WO2015132708A1 (en) | Pharmaceutical composition of roflumilast | |
| JP2018504443A5 (https=) | ||
| WO2011160541A1 (zh) | 托伐普坦固体分散体及其制备方法 | |
| BR102013020508A2 (pt) | forma de dosagem que compreende um inibidor de esteróide 5-alfa-redutase e um bloqueador alfa, processo para a preparação de uma forma de dosagem, uso da forma de dosagem, método para o tratamento ou profilaxia de uma doença ou condição mediada por andrógeno | |
| HRP20200780T1 (hr) | Formulacija za kontrolirano otpuštanje hidrokortizona | |
| TW201110968A (en) | A thrombin receptor antagonist and clopidogrel fixed dose tablet |